Re:Top cancer researcher fails to disclose corporate ties in...
by Gatsky on Sunday September 09, 2018 @07:36AM
(#17945429)
No, Baselga is primarily a clinical trialist, so it isn’t relevant to this discussion.
Clinical trials have standardised designs and procedures, the number of experimental subjects is large (compared to preclinical lab experiments), and orthogonal outcome measures are collected to enhance validity (like response rate and survival outcomes). Most doctors are trained and experienced in interpreting clinical trials, and are well aware of the limitations, which are constantly highlighted in conference discussions and the literature.
Finally, clinical trials are replicated all the time (surprised you would suggest otherwise?). A drug is tested in phase 1, phase 2 and phase 3 trials of increasing size, and drugs from the same class are also tested in competing trials.
Clinical trials have standardised designs and procedures, the number of experimental subjects is large (compared to preclinical lab experiments), and orthogonal outcome measures are collected to enhance validity (like response rate and survival outcomes). Most doctors are trained and experienced in interpreting clinical trials, and are well aware of the limitations, which are constantly highlighted in conference discussions and the literature.
Finally, clinical trials are replicated all the time (surprised you would suggest otherwise?). A drug is tested in phase 1, phase 2 and phase 3 trials of increasing size, and drugs from the same class are also tested in competing trials.